Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor for Hypoxemia in Lung Disease
NCT05289570Phase 2Terminated
- Sponsor
- Duke University
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voxelotor in acute lung injury (ALI) and Lung disease, sponsored by Duke University. Primary endpoint: Change in SpO2/FiO2 (S/F) Ratio From Baseline to 2 Days After Initiation of Voxelotor Treatment. Started May 2022; status: terminated.
02
Drugs
voxelotor
03
Conditions
acute lung injury (ALI)Lung disease
Beyond the preview
Go deeper on NCT05289570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289570.